Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
Studying the genetics of leukaemia to find new treatments
Investigations into EVI1 mediated epigenetic modulation in childhood leukaemia